TrialBMC cancer2015

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.

Olga Grishina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.